|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
140,280,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development of genetically engineered allogeneic T cell therapies for the treatment of cancer. Co.'s key product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic Chimeric antigen receptor (CAR) T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. Co. is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma, and other blood cancers and solid tumors.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,724,137 |
1,724,327 |
1,724,327 |
1,724,327 |
Total Buy Value |
$4,999,997 |
$5,000,680 |
$5,000,680 |
$5,000,680 |
Total People Bought |
1 |
2 |
2 |
2 |
Total Buy Transactions |
1 |
2 |
2 |
2 |
Total Shares Sold |
0 |
18,640 |
28,640 |
71,242 |
Total Sell Value |
$0 |
$50,317 |
$93,172 |
$615,058 |
Total People Sold |
0 |
1 |
2 |
5 |
Total Sell Transactions |
0 |
1 |
2 |
11 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bhavnagri Veer |
General Counsel |
|
2020-10-06 |
4 |
AS |
$40.00 |
$400,000 |
D/D |
(10,000) |
353,902 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-10-06 |
4 |
OE |
$2.27 |
$22,700 |
D/D |
10,000 |
363,902 |
|
- |
|
Amado Rafael |
EVP of R&D and CMO |
|
2020-10-01 |
4 |
S |
$36.37 |
$354,662 |
D/D |
(9,752) |
128,215 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-10-01 |
4 |
AS |
$36.21 |
$912,913 |
D/D |
(25,000) |
353,902 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-10-01 |
4 |
OE |
$2.27 |
$56,750 |
D/D |
25,000 |
378,902 |
|
- |
|
Schmidt Eric Thomas |
Chief Financial Officer |
|
2020-09-21 |
4 |
AS |
$34.76 |
$529,545 |
I/I |
(15,000) |
1,212,595 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-09-01 |
4 |
AS |
$35.35 |
$883,966 |
D/D |
(25,000) |
353,902 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-09-01 |
4 |
OE |
$2.27 |
$56,750 |
D/D |
25,000 |
378,902 |
|
- |
|
Chang David D |
President and CEO |
|
2020-08-31 |
4/A |
GA |
$0.00 |
$0 |
I/I |
411,556 |
856,044 |
|
- |
|
Moore Alison |
Chief Technical Officer |
|
2020-08-13 |
4 |
OE |
$2.27 |
$73,664 |
D/D |
32,451 |
126,272 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-08-07 |
4 |
AS |
$37.02 |
$497,236 |
I/I |
(13,291) |
18,716,306 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-08-06 |
4 |
AS |
$37.33 |
$905,794 |
I/I |
(24,154) |
18,729,597 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-08-06 |
4 |
AS |
$0.00 |
$0 |
I/I |
(962,555) |
18,753,751 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-08-03 |
4 |
AS |
$36.46 |
$1,164,121 |
D/D |
(31,553) |
353,902 |
|
- |
|
Bhavnagri Veer |
General Counsel |
|
2020-08-03 |
4 |
OE |
$2.27 |
$56,750 |
D/D |
25,000 |
385,455 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-25 |
4 |
S |
$44.19 |
$3,197,327 |
I/I |
(72,359) |
19,801,457 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-24 |
4 |
S |
$43.93 |
$670,714 |
I/I |
(15,269) |
19,873,816 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-23 |
4 |
S |
$43.91 |
$5,814,610 |
I/I |
(132,225) |
19,889,085 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-22 |
4 |
S |
$42.72 |
$7,384,721 |
I/I |
(172,425) |
20,021,310 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-19 |
4 |
S |
$42.04 |
$2,008,306 |
I/I |
(47,767) |
20,193,735 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-18 |
4 |
S |
$42.14 |
$3,986,595 |
I/I |
(94,600) |
20,241,502 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-17 |
4 |
S |
$42.18 |
$3,683,482 |
I/I |
(87,319) |
20,336,102 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-16 |
4 |
S |
$42.20 |
$7,364,678 |
I/I |
(174,511) |
20,423,421 |
|
- |
|
Coulter James G |
10% Owner |
|
2020-06-15 |
4 |
S |
$42.14 |
$5,442,885 |
I/I |
(129,154) |
20,597,932 |
|
- |
|
Witte Owen N. |
|
|
2020-06-05 |
4 |
A |
$0.00 |
$0 |
D/D |
9,969 |
246,151 |
|
- |
|
225 Records found
|
|
Page 6 of 9 |
|
|